MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3233/jhd-140110

Медицинская библиотека · Journal of Huntington's disease · 2014

Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.

Corey-Bloom Jody, Jia Haiqun, Aikin Alaina M, Thomas Elizabeth A

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Deficiencies in brain-derived-neurotrophic-factor have been implicated in the pathogenesis of Huntington's disease (HD).

OBJECTIVE

Glatiramer acetate, an FDA- approved drug used for the treatment of multiple sclerosis, has been shown to increase brain-derived-neurotrophic-factor levels in immune cells; hence, we investigated whether it could have similar effects in striatal cells.

METHODS

Wild-type and HD striatal cells were treated with glatiramer acetate for 48 hrs. HD transgenic and wild-type mice were injected with glatiramer acetate (1.5 to 1.7 mg/mouse) for five days. These treatments were followed by protein measurements for brain-derived-neurotrophic-factor.

RESULTS

Glatiramer acetate elicited concentration-dependent increases in brain-derived-neurotrophic-factor protein levels in wild-type and HD striatal cells and in striatal tissue from N171-82Q transgenic mice. Glatiramer acetate also improved metabolic activity of HD striatal cells, and significantly reduced the early hyperactivity phenotype exhibited by N171-82Q transgenic mice.

CONCLUSIONS

These findings suggest that glatiramer acetate may represent a useful therapeutic approach for HD. The excellent safety and tolerability record of this compound makes it an ideal candidate for drug repurposing efforts.

Для цитирования: Corey-Bloom Jody, Jia Haiqun, Aikin Alaina M, Thomas Elizabeth A. Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.. Journal of Huntington's disease. 2014. DOI: 10.3233/jhd-140110.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.